The pathological aggregation of the microtubule-associated protein tau is a hallmark of various neurodegenerative disorders, including Alzheimer’s disease (AD), Pick’s disease and frontotemporal dementia. Tau protein’s reversible assembly and binding to microtubules in brain neurons are regulated by charge-neutralizing phosphorylation. Hyperphosphorylation, on the other hand, leads to irreversible formation of cytotoxic filaments. Under physiological conditions, tau remains remarkably stable, exhibiting intrinsically disordered behavior and reversible assembly. Irreversible aggregation requires specific mutations, preformed seeds or nucleating polyanionic cofactors. However, heparin-induced fibrils differ structurally from brain-derived filaments, and the presence of such cofactors can impede therapeutic agent development. We have developed a quick and easy method to generate cofactor-free filaments using heterogeneous electroreduction as a surrogate for charge-neutralization by hyperphosphorylation. We combine electrochemistry with in situ UV absorbance, circular dichroism and dynamic light scattering spectroscopies to dynamically follow tau’s conformational changes and assembly. Electroreduction of positively charged residues of the protein leads to rapid formation of b-rich structures, even at times as short as 15 minutes. The extent of assembly can be controlled by fine-tuning electroreductive potentials and electrolyte conditions. Relevance of this new method was confirmed by examining the impact of an early-onset AD-causing tau mutant and known inhibitors on aggregation kinetics. Our results demonstrate comparable effects to heparin-induced fibrils, as assessed by thioflavin-T fluorescence, dynamic light scattering, circular dichroism and electron microscopy. Low-voltage electroreduction provides a platform to study the effects of tau mutations and effectors, as well as to develop rapid assays to test how additional effectors may inhibit, disassemble or direct the trajectory of tau assembly. The versatility of our approach also suggests its potential applicability to a broader spectrum of neurodegenerative amyloid diseases.